You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers

    SBC: KinaRx, LLC            Topic: 102

    Over the past three decades a growing number of cancer-driving protein kinases have been successfully targeted as reflected in the approval of 49 kinase inhibitors by the Food and Drug Administration (FDA). Recent approval of the first tyrosine kinase inhibitor (Larotrectinib) for treatment of any cancer bearing mutation in neurotrophic receptor kinase validated a novel paradigm of precision targe ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. A New Oxygen Recovery Process to Reduce Waste from Propellant Tanks

    SBC: TDA RESEARCH, INC.            Topic: T2

    After landing, the lunar lander liquid oxygen tank may contain as much as 5% residual oxygen that is pressurized with helium. TDA Research proposes to develop an oxygen recovery module which separates the helium from the oxygen so that the remaining high purity oxygen can be readily supplied to life-support equipment and fuel cells. The oxygen recovery module uses an advanced sorbent that has a hi ...

    STTR Phase I 2020 National Aeronautics and Space Administration
  4. A Novel Liquid Hydrogen/Oxygen Co-generator

    SBC: TDA RESEARCH, INC.            Topic: N/A

    NASA¿s objective for affordable access to space requires inexpensive production of rocket fuel. The key to achieving this objective is the production of hydrogen, since hydrogen accounts for more than 80% of the fuel cost. TDA Research, Inc. (TDA), collaborating with Louisiana State University (LSU), proposes a novel hydrogen production method that offers significant advantages over conventiona ...

    STTR Phase I 2001 National Aeronautics and Space Administration
  5. A Novel Liquid Hydrogen/Oxygen Co-generator

    SBC: TDA RESEARCH, INC.            Topic: N/A

    NASA¿s objective for affordable access to space requires inexpensive production of rocket fuel. The key to achieving this objective is the production of hydrogen, since hydrogen accounts for more than 80% of the fuel cost. TDA Research, Inc. (TDA), collaborating with Louisiana State University (LSU), proposes a novel hydrogen production method that offers significant advantages over conventiona ...

    STTR Phase II 2001 National Aeronautics and Space Administration
  6. A novel monobody-drug conjugate to treat mutant Ras multiple myeloma

    SBC: TEZCAT Laboratories LLC            Topic: 102

    Project Summary: Multiple myeloma is an incurable hematologic malignancy with an expected median survival of 7-8 years. The proteasome inhibitors, bortezomib, carfilzomib and the recently approved ixazomib, are a mainstay of current myeloma treatment. Despite an initial response rate approaching 90% to proteasome inhibitor-containing combinations, all patients relapse and eventually become resista ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement

    SBC: POLYNOVA CARDIOVASCULAR INC            Topic: NHLBI

    Project Summary: A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet clinical need of inoperable patients with severe aortic stenosis (AS). Recent longitudinal follow-up studies of TAVR patients however indicate that this procedure and associated technology may result i ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Strategy for Diagnosis of Esophageal Adenocarcinoma.

    SBC: CAPSULOMICS INC            Topic: 102

    Contact PD/PI: Abraham, John M Esophageal adenocarcinoma (EAC) is one of two major types of esophageal cancer, which causes 509,000 deaths worldwide annually. EAC diagnosis is made using the invasive, expensive, risky, and not universally accessible procedure, esophagogastroduodenoscopy (EGD). Thus, there is a pressing need for easier, safer, cheaper strategies for EAC diagnosis. Our novel strateg ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A PET Diagnostic for Imaging Bacterial Infection

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIBIB

    PROJECT SUMMARY Bacterial infections such as those of prosthetic joints, bones (osteomyelitis) and heart valves (infective endocarditis) are difficult to diagnose and treat, and are a major cause of mortality, morbidity and health care costs. The long-term goal of our program is to develop a positron emission tomography (PET) radiotracer that can be used for non-invasive PET imaging to detect and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Automated Monitoring of Chemotactic Cell Movement

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION ( provided by applicant): The ECIS/taxis technology can detect cells that move to a small electrode through an agarose matrix by the resistance that they impart to an electrical circuit as they cover parts of the small electrode. This system is amenable to rapid throughput analysis of cell behavior in the presence of chemokines and other agents that ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government